It’s because the trial choose the wrong primary endpoint which didn’t reach the efficacy they would’ve wanted so people are completely ignoring the other 5 parts that did amazingly!
Even on the call dr Budoff said if they chose one of the other endpoints (forgot which it was called but the one with .0004 p value) they would’ve stopped the trial for efficacy.
No doubt. This is my favorite 6% sell off of all-time. We're down because Vascepa reduces overall plaque by 42% in 9 months and is on target to meet the primary endpoint after 18 months! ;)
Raf-Dr. Budoff said trial failed the primary endpoint-listen to the interview I posted yesterday. Yes, we hope by 18 months it will succeed, but at 9 months it failed to prevent enough attenuated plaque--which is the dangerous plaque that ruptures and causes heart attacks.
We both know now that that is why Dr. Budoff continued the trial b/c the p. endpoint WAS NOT met.
btw--we are only discussing prevention not removal of plaque. that was only 1%.
News 
Market Data 
Discover 
AI
